Edoxaban

May 11, 2020

Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

Oct 28, 2019

Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding

Jul 31, 2019

Global Anticoagulants (Xarelto, Eliquis, Pradaxa, Savaysa) Market 2019-2023

May 31, 2019

Anticoagulants Market, 2024 - Focus on Oral Anticoagulants & Injectable Anticoagulants (Unfractionated Heparin, & Low Molecular Weight Heparin)

Mar 01, 2019

Anticoagulants - Global Market Outlook to 2024 with Profiles on 48 Players

Jan 22, 2019

Global Anticoagulants Industry

Dec 04, 2018

Perosphere Pharmaceuticals' Ciraparantag Research Presented at American Society of Hematology Annual Meeting

Sep 08, 2018

Aniara Diagnostica Launches http://www.DOACtesting.com Providing Specific Product Information For Direct Oral Anticoagulant Testing

Dec 15, 2017

Once-Daily Oral Anticoagulant LIXIANA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

Dec 12, 2017

Once-Daily, Oral SAVAYSA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

Aug 29, 2017

New Sub-analysis Data Highlights the Benefit of LIXIANA(R) (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring